PTC Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO PTC Therapeutics is Matt Klein, benoemd in Mar2023, heeft een ambtstermijn van 3.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 23.27M, bestaande uit 4.1% salaris en 95.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.15% van de aandelen van het bedrijf, ter waarde $ 8.08M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.4 jaar en 7.3 jaar.
Belangrijke informatie
Matt Klein
Algemeen directeur
US$23.3m
Totale compensatie
| Percentage CEO-salaris | 4.12% |
| Dienstverband CEO | 3.1yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 6.4yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
PTCT: Early Neurology Launch And Pipeline Progress Will Support Bullish 2026 Outlook
Analysts have nudged their average price target for PTC Therapeutics higher to about $88 from roughly $86.50. This reflects updates to models after recent Q4 commentary, revised views on revenue trends, margin expectations, and future P/E assumptions.PTCT: Early Neurology Launch Execution Will Drive Bullish 2026 Outlook
Narrative Update on PTC Therapeutics The analyst price target for PTC Therapeutics has been trimmed from $87.93 to $86.50 as analysts balance generally higher Street targets and improved profit margin assumptions with slightly softer revenue growth expectations and a more conservative future P/E. Analyst Commentary Recent research updates on PTC Therapeutics show a mix of optimism and caution, with several analysts adjusting price targets after the Q4 report, Sephience launch updates, and broader sector views.
PTCT: Future Earnings Power Will Be Driven By Growing PKU And Huntington’s Pipelines
Analysts have raised PTC Therapeutics' consensus price target from the low $90s to around $120, citing updated Q4 results, early Sephience traction, and expectations that newer revenue streams could offset pressure in the DMD franchise. Analyst Commentary Recent research on PTC Therapeutics has leaned constructive, with several bullish analysts tying higher valuation ranges to execution around Sephience, updated Q4 commentary, and the broader revenue mix.PTCT: Future Earnings Power Will Be Driven By Expanding PKU And Huntington’s Franchises
The analyst price target for PTC Therapeutics has been raised by $6.61, with analysts pointing to stronger modeled revenue growth, higher profit margins, and updated P/E assumptions following recent Q4 commentary and comparative advantages in Huntington's disease treatments. Analyst Commentary Recent Street research around PTC Therapeutics has been broadly constructive, with several bullish analysts adjusting their models after the Q4 update and early Sephience launch commentary.PTC Therapeutics: Sephience As A Major Growth Driver
Feb 23PTCT: Sephience Execution Will Drive Bullish 2026 Outlook Despite DMD Pressure
Narrative Update: PTC Therapeutics The analyst price target for PTC Therapeutics has shifted modestly lower to align with our updated fair value of about $87.93, as analysts weigh mixed revisions to revenue growth and profitability assumptions against ongoing support from Sephience-driven estimates. Analyst Commentary Recent Street research on PTC Therapeutics centers on how Sephience trends could influence the company’s revenue mix, profitability path, and valuation, especially as the DMD franchise faces pressure.PTCT: Index Additions And Pipeline Execution Will Shape Bullish 2026 Outlook
Analysts have raised their fair value estimate for PTC Therapeutics to about $88.50 from $81.86, reflecting updated views on the discount rate, revenue trends, profit expectations, and a higher assumed future P/E that aligns with recent price target increases from several research firms. Analyst Commentary Recent Street research on PTC Therapeutics has focused on price target adjustments and rating changes, which feed directly into how analysts think about valuation, execution risk, and potential growth opportunities.
PTCT: Single-Drug Dependence Will Likely Limit Upside Despite Strong Launch Start
Narrative Update: PTC Therapeutics (PTCT) The analyst price target for PTC Therapeutics is updated in line with a series of upward Street revisions, as analysts point to stronger than expected Sephience launch metrics and recent Q3 outperformance, along with generally supportive views on small to mid cap biotech heading into 2026. Analyst Commentary Street research on PTC Therapeutics has leaned positive around the Q3 report and the Sephience launch, with several large firms lifting price targets after what they describe as strong initial commercial execution.PTCT: Future Earnings Power Will Be Driven By Expanding PKU Franchise
The analyst price target for PTC Therapeutics has been raised from about $103 to about $115. Analysts cited stronger Sephience launch trends, a shift in the modeled profit margin to 34%, a more moderate future P/E near 20x, and a less conservative revenue outlook as key drivers of the change.PTCT Overreliance On Single Drug Will Likely Cap Share Price Upside
The analyst fair value estimate for PTC Therapeutics has been raised from $44.00 to $55.00 per share as analysts factor in stronger than expected Sephience launch metrics, upwardly revised price targets across the Street, and improving confidence in the durability of the company’s growth trajectory. Analyst Commentary Recent Street research has broadly welcomed PTC Therapeutics Q3 performance and the stronger than expected Sephience launch, with several major firms lifting their price targets.PTCT: Launch Momentum And Index Additions Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by about $1.36 to roughly $81.86, as analysts highlight stronger than expected Sephience launch metrics, improving revenue and margin assumptions, and sustained post earnings momentum. Analyst Commentary Analysts are broadly constructive on PTC Therapeutics following its latest earnings, citing Sephience outperformance and improving visibility into the company’s growth trajectory.PTCT: Revenue Outlook And New Launch Performance Will Influence 2025 Assessment
Analysts have raised their price target for PTC Therapeutics from approximately $77.93 to $80.50, citing stronger-than-expected Sephience sales and continued momentum following the company's latest earnings report. Analyst Commentary Recent reports from Wall Street analysts reflect a range of views regarding PTC Therapeutics' execution and growth prospects, primarily driven by the company's strong recent earnings and the launch of Sephience.PTCT: Revenue Guidance Narrowing And Launch Momentum Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by $10, as analysts cite stronger-than-expected Sephience sales and increasing momentum following the company's recent earnings beat. Analyst Commentary Recent analyst reports on PTC Therapeutics highlight a wide range of perspectives following the company’s robust third-quarter results and new product launches.Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
Analysts have increased their average price target for PTC Therapeutics by approximately $1.25 to $67.93. They cite heightened community interest in Sephience, improved profit margin forecasts, and overall strong sentiment for upcoming launches, despite recent regulatory setbacks.PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Shares Bounce 26% But Its Business Still Trails The Industry
Sep 08
Broad Approvals Will Elevate Rare Disease Markets Despite Setbacks
Analysts lowered their price targets for PTC Therapeutics following the FDA's Complete Response Letter for vatiquinone, citing the removal of Friedreich's ataxia revenues and increased regulatory uncertainty, though encouraging early signals from the Sephience launch and its broad approval label partially offset downside, resulting in a modest consensus target reduction from $68.31 to $66.69. Analyst Commentary Bullish analysts highlight the recent selloff post-FDA Complete Response Letter (CRL) for vatiquinone in Friedreich's ataxia as a buying opportunity, believing negative outcomes were anticipated and already priced into shares.Solid Earnings Reflect PTC Therapeutics' (NASDAQ:PTCT) Strength As A Business
May 13
2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs
Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues.PTC Therapeutics: Upside In Rare Disease Innovation
Mar 09PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
Nov 29Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2025 | US$23m | US$959k | US$683m |
| Sep 30 2025 | n/a | n/a | US$752m |
| Jun 30 2025 | n/a | n/a | US$629m |
| Mar 31 2025 | n/a | n/a | US$595m |
| Dec 31 2024 | US$7m | US$882k | -US$363m |
| Sep 30 2024 | n/a | n/a | -US$453m |
| Jun 30 2024 | n/a | n/a | -US$480m |
| Mar 31 2024 | n/a | n/a | -US$579m |
| Dec 31 2023 | US$9m | US$747k | -US$627m |
| Sep 30 2023 | n/a | n/a | -US$642m |
| Jun 30 2023 | n/a | n/a | -US$618m |
| Mar 31 2023 | n/a | n/a | -US$571m |
| Dec 31 2022 | US$5m | US$598k | -US$559m |
Compensatie versus markt: De totale vergoeding ($USD 23.27M ) Matt } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.44M ).
Compensatie versus inkomsten: De vergoeding van Matt is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Matt Klein (52 yo)
3.1yrs
Tenure
US$23,266,326
Compensatie
Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, is Trustee of BioNJ Inc. Dr. Klein serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Ind...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | US$23.27m | 0.15% $ 8.1m | |
| Co-Founder & Independent Director | 28.3yrs | US$547.41k | 0.018% $ 975.7k | |
| Chief Financial Officer | 2.8yrs | US$3.55m | 0.034% $ 1.8m | |
| Chief Technical Operations Officer | 7.3yrs | US$3.16m | 0.019% $ 1.0m | |
| Chief Business Officer | 11yrs | US$3.56m | 0.030% $ 1.6m | |
| Executive VP & Chief Medical Officer | 5.9yrs | US$3.27m | 0.034% $ 1.8m | |
| Senior VP | 6.8yrs | US$1.70m | 0.048% $ 2.5m | |
| Senior VP & Chief Information Officer | 1.5yrs | geen gegevens | geen gegevens | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief Legal Officer | 14.1yrs | US$2.19m | 0.13% $ 6.8m | |
| Vice President of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 5.5yrs | geen gegevens | geen gegevens |
6.4yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PTCT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | US$23.27m | 0.15% $ 8.1m | |
| Co-Founder & Independent Director | 28.3yrs | US$547.41k | 0.018% $ 975.7k | |
| Independent Chairman of the Board | 24.7yrs | US$896.31k | 1.85% $ 99.2m | |
| Independent Director | 20.3yrs | US$494.41k | 0.018% $ 937.1k | |
| Independent Director | 13.6yrs | US$463.91k | 0.019% $ 1.0m | |
| Independent Director | 7.3yrs | US$507.41k | 0.0080% $ 430.3k | |
| Independent Director | 10.8yrs | US$477.41k | 0.019% $ 1.0m | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 3.8yrs | US$475.91k | 0.018% $ 951.0k | |
| Independent Director | 7.3yrs | US$471.91k | 0.0068% $ 365.5k | |
| Independent Director | 4.8yrs | US$479.41k | 0.019% $ 999.2k |
7.3yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PTCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/04/30 03:47 |
| Aandelenkoers aan het einde van de dag | 2026/04/30 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
PTC Therapeutics, Inc. wordt gevolgd door 35 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Luke Herrmann | Baird |
| Joel Beatty | Baird |
| null null | Baird |